ATE432506T1 - Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease - Google Patents
Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-proteaseInfo
- Publication number
- ATE432506T1 ATE432506T1 AT03761598T AT03761598T ATE432506T1 AT E432506 T1 ATE432506 T1 AT E432506T1 AT 03761598 T AT03761598 T AT 03761598T AT 03761598 T AT03761598 T AT 03761598T AT E432506 T1 ATE432506 T1 AT E432506T1
- Authority
- AT
- Austria
- Prior art keywords
- drug
- hiv
- drug resistance
- phenotypical
- protease
- Prior art date
Links
- 206010059866 Drug resistance Diseases 0.000 title abstract 2
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 title 1
- 230000002596 correlated effect Effects 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
- 230000000869 mutational effect Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009510 drug design Methods 0.000 abstract 1
- 238000009509 drug development Methods 0.000 abstract 1
- 238000007876 drug discovery Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- AIDS & HIV (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39275302P | 2002-07-01 | 2002-07-01 | |
| PCT/EP2003/050277 WO2004003817A1 (en) | 2002-07-01 | 2003-06-30 | Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE432506T1 true ATE432506T1 (de) | 2009-06-15 |
Family
ID=30000930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03761598T ATE432506T1 (de) | 2002-07-01 | 2003-06-30 | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7217506B2 (de) |
| EP (1) | EP1520247B1 (de) |
| AT (1) | ATE432506T1 (de) |
| AU (1) | AU2003254500B2 (de) |
| CA (1) | CA2490862A1 (de) |
| DE (1) | DE60327768D1 (de) |
| WO (1) | WO2004003817A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01012270A (es) * | 1999-05-28 | 2003-06-24 | Virco Nv | Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos. |
| AU2002226316B2 (en) * | 2000-10-20 | 2008-06-26 | Virco Bvba | Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance |
| US20050214744A1 (en) * | 2002-07-01 | 2005-09-29 | Hilde Azjin | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| CA2490764C (en) * | 2002-07-01 | 2011-11-22 | Tibotec Pharmaceuticals Ltd. | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| EP1520247B1 (de) | 2002-07-01 | 2009-05-27 | Tibotec Pharmaceuticals Ltd. | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
| US7372540B2 (en) * | 2004-10-12 | 2008-05-13 | Asml Netherlands B.V. | Lithographic apparatus and device manufacturing method |
| ES2331257T3 (es) | 2005-02-25 | 2009-12-28 | Tibotec Pharmaceuticals | Sintesis de precursores de inhibidores de proteasas. |
| EP2458019A3 (de) * | 2005-05-27 | 2012-07-25 | Monogram BioSciences, Inc. | Verfahren und Zusammensetzungen zum Bestimmen der HIV-1-Beständigkeit gegenüber Proteasehemmern |
| CA2637203A1 (en) * | 2006-01-19 | 2007-07-26 | Monogram Biosciences, Inc. | Method for determining resistance of hiv to protease inhibitor treatment |
| AU2007211495B2 (en) * | 2006-02-03 | 2012-11-15 | Virco Bvba | Quantitative HIV phenotype or tropism assay |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US327742A (en) * | 1885-10-06 | Machine for making nuts | ||
| GB2229340B (en) | 1989-03-17 | 1994-02-09 | Technophone Ltd | Radio telephone system |
| GB8918226D0 (en) | 1989-08-09 | 1989-09-20 | Wellcome Found | Dna assays |
| EP0428000A1 (de) | 1989-11-03 | 1991-05-22 | Abbott Laboratories | Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität |
| US5235039A (en) | 1991-06-10 | 1993-08-10 | Eli Lilly And Company | Substrates for hiv protease |
| WO1993023574A1 (en) * | 1992-05-14 | 1993-11-25 | Kozal Michael J | Polymerase chain reaction assays for monitoring antiviral therapy |
| US6063562A (en) | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
| US5685141A (en) | 1995-12-26 | 1997-11-11 | General Electric Company | Lock for nozzle control in the event of hydraulic failure |
| HU226203B1 (en) * | 1996-01-26 | 2008-06-30 | Virco B V B A | Method for determining of the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
| BR9704637A (pt) | 1996-01-26 | 1998-06-09 | Innogenetics Nv | Processo para deteção de mutações induzidas por droga no gene de transcrição reversa |
| ES2175355T3 (es) | 1996-01-29 | 2002-11-16 | Virologic Inc | Composiciones y metodos para determinar la susceptibilidad y la resistencia a farmacos antivirales y rastreo de farmacos antivirales. |
| JP3062459B2 (ja) | 1996-08-14 | 2000-07-10 | 理化学研究所 | ポリエステル重合酵素遺伝子及びポリエステルの製造方法 |
| BR9911600A (pt) | 1998-05-26 | 2001-02-13 | Virologic Inc | Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo |
| WO1999061666A1 (en) | 1998-05-28 | 1999-12-02 | Visible Genetics Inc. | Use of polymorphisms as a predictor of drug-resistance mutations |
| PT2336134T (pt) | 1998-06-23 | 2016-10-19 | The Board Of Trustees Of The Univ Of Illionis | Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia |
| CA2330234A1 (en) | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Method for detection of drug-selected mutations in the hiv protease gene |
| CN1154747C (zh) | 1998-06-24 | 2004-06-23 | 病毒科学公司 | 监控核苷类逆转录酶抑制剂抗逆转录病毒治疗和在治疗hiv/aids中指导治疗决定的途径与方法 |
| MXPA01012270A (es) | 1999-05-28 | 2003-06-24 | Virco Nv | Nuevos perfiles mutacionales en la transcriptasa reversa de vih-1 correlacionadas con resistencia fenotipica a farmacos. |
| EP1194587A4 (de) | 1999-06-22 | 2005-07-06 | Virologic Inc | Mittel und verfahren zum überwachen von antiretroviralen therapien mit proteaseinhibitorenund entscheidungshilfe bei therapien in der behandlung von hiv/aids |
| WO2000078994A1 (en) | 1999-06-23 | 2000-12-28 | The Penn State Research Foundation | Compositions and methods for the quantification of sterol biosynthetic flux |
| WO2001079540A2 (en) | 2000-04-18 | 2001-10-25 | Virco Bvba | Methods for measuring drug resistance |
| CA2406830C (en) | 2000-04-20 | 2012-10-02 | Virco Bvba | Method for mutation detection in hiv using pol sequencing |
| US7058616B1 (en) * | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
| US20030190603A1 (en) * | 2000-06-08 | 2003-10-09 | Brendan Larder | Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks |
| WO2002022076A2 (en) | 2000-09-15 | 2002-03-21 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| ATE422049T1 (de) | 2000-10-20 | 2009-02-15 | Virco Bvba | Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz |
| AU2002226316B2 (en) * | 2000-10-20 | 2008-06-26 | Virco Bvba | Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance |
| JP2002199890A (ja) | 2000-10-23 | 2002-07-16 | Inst Of Physical & Chemical Res | 生分解性ポリエステル合成酵素の改変方法 |
| JP2005500003A (ja) | 2000-11-10 | 2005-01-06 | バイオオーリアンス ファーマ | ヒト免疫不全ウイルス（ｈｉｖ）の表現型特性の新規な分析法 |
| EP1370543B1 (de) | 2001-02-14 | 2006-10-25 | Tibotec Pharmaceuticals Ltd. | Breitspektrum 2-(substituierte-amino)-benzothiazol-sulfonamide hiv protease inhibitoren |
| US20050214744A1 (en) * | 2002-07-01 | 2005-09-29 | Hilde Azjin | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| EP1520247B1 (de) | 2002-07-01 | 2009-05-27 | Tibotec Pharmaceuticals Ltd. | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease |
| CA2490764C (en) * | 2002-07-01 | 2011-11-22 | Tibotec Pharmaceuticals Ltd. | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| RU2357962C2 (ru) | 2002-09-06 | 2009-06-10 | Элан Фармасьютикалз, Инк. | Пролекарственные производные 1,3-диамино-2-гидроксипропана |
| EP1605064A1 (de) | 2004-06-07 | 2005-12-14 | UMC Utrecht Holding B.V. | HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind. |
-
2003
- 2003-06-30 EP EP03761598A patent/EP1520247B1/de not_active Expired - Lifetime
- 2003-06-30 US US10/519,035 patent/US7217506B2/en not_active Expired - Fee Related
- 2003-06-30 CA CA002490862A patent/CA2490862A1/en not_active Abandoned
- 2003-06-30 DE DE60327768T patent/DE60327768D1/de not_active Expired - Lifetime
- 2003-06-30 AT AT03761598T patent/ATE432506T1/de not_active IP Right Cessation
- 2003-06-30 WO PCT/EP2003/050277 patent/WO2004003817A1/en not_active Ceased
- 2003-06-30 AU AU2003254500A patent/AU2003254500B2/en not_active Ceased
-
2006
- 2006-12-20 US US11/613,584 patent/US8592161B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1520247A1 (de) | 2005-04-06 |
| WO2004003817A1 (en) | 2004-01-08 |
| US7217506B2 (en) | 2007-05-15 |
| CA2490862A1 (en) | 2004-01-08 |
| DE60327768D1 (de) | 2009-07-09 |
| US20070269816A1 (en) | 2007-11-22 |
| AU2003254500B2 (en) | 2009-11-19 |
| EP1520247B1 (de) | 2009-05-27 |
| US20050233312A1 (en) | 2005-10-20 |
| AU2003254500A1 (en) | 2004-01-19 |
| US8592161B2 (en) | 2013-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0011555A (pt) | Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga | |
| Walter et al. | Genomic variant-identification methods may alter Mycobacterium tuberculosis transmission inferences | |
| GB0712154D0 (en) | Method for evaluating correlations between structured and normalized information on genetic variations between humans and their personal clinical patient data | |
| SE0003286D0 (sv) | Method and kit for human identification | |
| EP1490489A4 (de) | Verfahren und mittel zur überwachung und modulation des gen-silencing | |
| DE60327768D1 (de) | Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease | |
| WO2003100557A3 (en) | Computer systems and methods for subdividing a complex disease into component diseases | |
| WO2007061881A3 (en) | Systems and methods for the biometric analysis of index founder populations | |
| EP1565582A4 (de) | Verfahren zur identifizierung des brustkrebsrisikos und behandlungen davon | |
| WO2004043232A3 (en) | Methods for identifying risk of melanoma and treatments thereof | |
| ATE397669T1 (de) | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase | |
| WO2003078603A3 (en) | Strong gene sets for glioma classification | |
| MXPA03003476A (es) | Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco. | |
| WO2002022076A3 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids | |
| ATE375400T1 (de) | Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren | |
| EP1407042A4 (de) | Mittel und verfahren zur überwachung einer antiretroviralen proteaseinhibitortherapie und als richtschnur für therapeutische entscheidungen bei der behandlung von hiv/aids | |
| ATE400666T1 (de) | Verwendung eines typ-iii-restriktionsenzyms zur isolierung von mehr als 25 nukleotide umfassenden sequenz-tags | |
| Petrone et al. | Mapping the global distribution and spread of the Plasmodium vivax-associated virus MaRNAV-1 | |
| KR200208239Y1 (ko) | 특정인의 ｄｎａ구조를 형상화한 팔찌 | |
| WO2003019189A1 (en) | Homogeneous phase gene microarray | |
| WO2005033280A3 (en) | Hiv-dependent expression constructs and uses therefor | |
| Lasek-Nesselquist et al. | A statewide analysis of SARS-CoV-2 transmission in New York | |
| AU2014347768A1 (en) | HCV genotyping algorithm | |
| DE60313366D1 (de) | Nukleinsäuresonden und Verfahren zum Nachweis einer Zielnukleinsäuresequenz mit zwei oder mehr cis-Nukleinsäurebereichen | |
| Guessous et al. | Trends in pharmacogenomic epidemiology: 2001–2007 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |